Feasibility and reliability of the revised Edmonton Symptom Assessment System (ESAS-r) in Egyptian patients with advanced cancer: A single institutional experience

Objective This study aims to test the acceptance, feasibility, and usefulness of the Arabic version of the revised Edmonton Symptom Assessment System (ESAS-r) among Egyptian patients with advanced cancer and to compare the rates of symptoms documented by patients and physicians. Methods Between August 2014 and February 2015, a total of 140 patients at Ain Shams University Hospitals in Cairo, Egypt received the Arabic version of the ESAS-r. For each patient, the ESAS-r was completed twice, first by the treating physician (as part of the basic assessment) and a second time by the patient, with a maximum of 2 hours between the two assessments. An additional survey was included to assess patients’ acceptance of the survey and their preferences. Results Out of 140 enrol ed patients in the study, 11 patients refused to complete the questionnaire, and 10 patients were excluded due to incomplete records in their medical records. Complete data was retrieved for 119 patients who were included for further analyses. The 78 (65%) patients declared that the test was clear and easy to complete. They were able to answer the test without help. Col ectively, tiredness and sense of wel-being were the most commonly encountered symptoms in ratings obtained by both patients and physicians. Tiredness was the only symptom showing a significant dif erence between the two rating methods, patient-rated scores being higher (P = 0.032). Cronbach’s alpha showed that both tests com-pleted by the physician and the patients were internal y consistent: the physician-rated test had a coef icient of 0.877, and the patient-rated test had a coef icient of 0.863. Al ESAS scores had good internal consis-tency, with a Cronbach’s alpha coef icient of 0.88. The internal consistency remained high after removal of individual symptom scores, with Cronbach’s alpha coef icients ranging from 0.823 to 0.902, indicating that no individual question had undue influence on the total ESAS score. Conclusion The ESAS-r was easily understood by and applicable to patients. There was no significant discrepancy in the rates of symptoms reported by the patients and physicians, apart from tiredness. Based on this, the test could be applied on a larger scale with in-home patients. This test can be cost-ef ective and can decrease the number of hospital visits among advanced cancer patients in need of supportive treat-ment rather than active cancer therapy.